Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
KEYTRUDA® Plus Padcev® Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR in Adults with Pulmonary Arterial Hypertension
FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm Larvae
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each with Padcev® , as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for WINREVAIR®
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir in Treatment-Naïve Adults with HIV-1 Infection
Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
Surface Sampling at Smart Creek Project Yields High-Grade Mineralization with up to 102 g/t Au, up to 23% Cu and up to 3810 g/t Ag
